• Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu

Non-Sponsored Content

CARDIOVASCULAR DISEASE

Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

Medical writer: Kirsty LEE | Last updated: 10th February 2021 | In: -, Cardiovascular

Article Keywords

atherosclerotic cardiovascular disease, cholesterol, hypercholesterolemia, LDL-C, myocardial infarction, registry

Evidence in recent years has shown that the lower the low-density lipoprotein cholesterol (LDL-C) levels, the lower the risk of future cardiovascular events.1Mach F et al. Eur Heart J. 2020;41(1):111-188.The 2019 ESC/EAS guidelines for the management of dyslipidaemias recommend very-high-risk cardiovascular patients to have an LDL-C reduction of ≥50% from baseline, and an LDL-C goal of <1.4 mmol/L (<55mg/dL).1Mach F et al. Eur Heart J. 2020;41(1):111-188. Very-high-risk patients include those with documented atherosclerotic cardiovascular disease, including a history of previous myocardial infarction (MI).1Mach F et al. Eur Heart J. 2020;41(1):111-188.

The SWEDEHEART registry is a Swedish nationwide MI registry that records the patient characteristics, medication, outcomes, and related interventions and preventions.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. All patients with an MI to any coronary care unit in Sweden are admitted to the registry.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The analysis included patients with an MI admitted between January 2006 and December 2016 who were between the ages of 30 and 75.2Schubert J et al. Eur Heart J. 2021;42(3):243-252.

A total of 40,607 MI patients were included in the analysis, with a median follow-up of 3.8 years.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. Median LDL-C at the time of the index event was 3.1 mmol/L in the overall population, and 3.4 mmol/L for statin-naïve patients, and 2.2 mmol/L for patients receiving statins.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The median LDL-C change was a 1.2 mmol/L reduction, with the largest mean LDL-C reductions being achieved in statin-naïve patients (mean reduction of 1.7 mmol/L).2Schubert J et al. Eur Heart J. 2021;42(3):243-252.

During the follow-up period, 7% patients died from any cause, 7% experienced a recurrent MI, and 11% had a major adverse cardiovascular event (MACE).2Schubert J et al. Eur Heart J. 2021;42(3):243-252. Patients with a larger LDL-C reduction (75th percentile with 1.85 mmol/L) had a lower risk of all outcomes compared to those with smaller LDL-C reductions (25th percentile with 0.36 mmol/L).2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The reduction in hazard ratio was linear across the interquartile range of LDL-C reduction for MACE, all-cause mortality, and MI.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. For every 1 mmol/L reduction in LDL-C, there was a ~25% relative event rate reduction in major vascular events.2Schubert J et al. Eur Heart J. 2021;42(3):243-252.

The results of this analysis of the SWEDEHEART registry demonstrate that early LDL-C reduction after MI is associated with lower incidence and greater risk reduction of MACE, all-cause mortality, cardiovascular mortality and MI.2Schubert J et al. Eur Heart J. 2021;42(3):243-252. The relationship between LDL-C and event rate reduction was linear, echoing the Cholesterol Treatment Trialists’ Collaboration meta-analysis of statins published in 2010.3Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Lancet Lond Engl. 2010;376(9753):1670-1681.

Reference

  1. Mach F et al. Eur Heart J. 2020;41(1):111-188.
  2. Schubert J et al. Eur Heart J. 2021;42(3):243-252.
  3. Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Lancet Lond Engl. 2010;376(9753):1670-1681.


Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Newsletter Sign-Up


YOU MAY ALSO LIKE

The evolution of hypertension management

The evolution of hypertension management

https://ftp.medi-paper.com/wp-content/uploads/2021/08/The-evolution-of-hypertension-management.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-08-20 16:34:052021-11-04 12:11:24The evolution of hypertension management
COVID-19 impacting regular patient care for cardiovascular diseases

COVID-19 impacting regular patient care for cardiovascular diseases

https://ftp.medi-paper.com/wp-content/uploads/2021/02/COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-17 11:52:282021-07-22 14:12:59COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

https://ftp.medi-paper.com/wp-content/uploads/2021/02/SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 15:41:562021-07-22 14:13:54SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia

Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia

https://ftp.medi-paper.com/wp-content/uploads/2020/10/data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 16:12:402020-10-12 16:01:55Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia
PreviousNext
The evolution of hypertension management
20th August 2021

The evolution of hypertension management

COVID-19 impacting regular patient care for cardiovascular diseases
17th February 2021

COVID-19 impacting regular patient care for cardiovascular diseases

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2021 MediPaper Medical Communications Ltd. – Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

YOU MAY ALSO LIKE

The evolution of hypertension management

The evolution of hypertension management

https://ftp.medi-paper.com/wp-content/uploads/2021/08/The-evolution-of-hypertension-management.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-08-20 16:34:052021-11-04 12:11:24The evolution of hypertension management
COVID-19 impacting regular patient care for cardiovascular diseases

COVID-19 impacting regular patient care for cardiovascular diseases

https://ftp.medi-paper.com/wp-content/uploads/2021/02/COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-17 11:52:282021-07-22 14:12:59COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

https://ftp.medi-paper.com/wp-content/uploads/2021/02/SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 15:41:562021-07-22 14:13:54SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia

Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia

https://ftp.medi-paper.com/wp-content/uploads/2020/10/data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 16:12:402020-10-12 16:01:55Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia
psoriasis-biologics-may-help-reduce-coronary-plaque

Psoriasis biologics may help reduce coronary plaque

https://ftp.medi-paper.com/wp-content/uploads/2020/10/psoriasis-biologics-may-help-reduce-coronary-plaque.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:45:112020-10-12 17:55:31Psoriasis biologics may help reduce coronary plaque
ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients

Ticagrelor may not confer post-MI benefits to elderly patients

https://ftp.medi-paper.com/wp-content/uploads/2020/10/ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:05:532020-10-12 16:00:51Ticagrelor may not confer post-MI benefits to elderly patients
Evidence-of-SARS-CoV2-in-heart-cells

Evidence of SARS-CoV2 in heart cells

https://ftp.medi-paper.com/wp-content/uploads/2020/09/Evidence-of-SARS-CoV2-in-heart-cells.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-22 10:19:272020-09-24 12:33:04Evidence of SARS-CoV2 in heart cells
risk-of-thrombosis-with-sars-cov-2-infection

Risk of thrombosis with SARS-CoV-2 infection

https://ftp.medi-paper.com/wp-content/uploads/2020/08/risk-of-thrombosis-with-sars-cov-2-infection-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-27 16:33:072020-09-24 12:37:30Risk of thrombosis with SARS-CoV-2 infection
further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure

Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results

https://ftp.medi-paper.com/wp-content/uploads/2020/08/further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure-scaled.jpg 1024 1818 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-25 14:40:232020-09-01 17:02:10Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results
potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

https://ftp.medi-paper.com/wp-content/uploads/2020/08/potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 15:28:132020-08-17 16:56:09Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations
Somazina citicoline small vessel disease vascular cognitive impairment traumatic brain injury neuroimaging cerebrovascular disorders ischaemic haemorraghic stroke rehabilitation neuroprotection

Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease

https://ftp.medi-paper.com/wp-content/uploads/2019/12/Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-12-16 10:35:082020-04-21 11:36:03Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease
Prof. Stephen Chan i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier

I-O in Special Populations: Chronic Viral Hepatitis Carriers

https://ftp.medi-paper.com/wp-content/uploads/2018/07/Prof.-Stephen-Chan-i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-18 21:51:462018-12-17 14:08:24I-O in Special Populations: Chronic Viral Hepatitis Carriers
TAVR transcatheter aortic valve replacement with Portico valve reduces severe aortic stenosis in real-world study PORTICO-1

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

https://ftp.medi-paper.com/wp-content/uploads/2018/09/TAVR-transcatheter-aortic-valve-replacement-with-Portico-valve-reduces-severe-aortic-stenosis-in-real-world-study-PORTICO-1-e1538119953610.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 15:23:462018-10-17 11:15:20Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study
TAVR vs SAVR - Transcatheter- vs surgical aortic valve replacement in high-risk patients 5-years survival

Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

https://ftp.medi-paper.com/wp-content/uploads/2018/09/TAVR-vs-SAVR-Transcatheter-vs-surgical-aortic-valve-replacement-in-high-risk-patients-5-years-survival.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 12:43:062018-10-17 11:13:32Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

Anti-coagulation: impact on long-term mortality and early valve dysfunction

https://ftp.medi-paper.com/wp-content/uploads/2018/09/cv7.jpg 905 1280 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-19 10:30:462018-09-19 20:45:35Anti-coagulation: impact on long-term mortality and early valve dysfunction

Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety

https://ftp.medi-paper.com/wp-content/uploads/2018/08/cv2.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-29 23:13:062018-08-29 23:13:06Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety

Febuxostat prevents CV events in hyperuricaemia patients

https://ftp.medi-paper.com/wp-content/uploads/2018/08/cv4.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-29 11:32:012018-10-04 14:52:10Febuxostat prevents CV events in hyperuricaemia patients

Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety

https://ftp.medi-paper.com/wp-content/uploads/2018/08/cv1.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 09:51:512018-08-30 10:05:16Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety
asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

https://ftp.medi-paper.com/wp-content/uploads/2016/05/asco-2016-nivolumab.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:44:422018-05-11 17:25:59ASCO16 Nivolumab (Opdivo©) Data
asco 2016 immune checkpoint inhibitors

ACC2016: 8½ Important Cardiology Lessons Learned

https://ftp.medi-paper.com/wp-content/uploads/2016/04/acc2016-chicago-take-away-messages.jpg 1024 1536 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-04-04 22:11:202017-11-25 14:09:33ACC2016: 8½ Important Cardiology Lessons Learned
PreviousNext

© Copyright 2021 MediPaper Medical Communications Ltd. – Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

Therapeutic Areas

Login

or
Login with Google
Login with Facebook
Login with Twitter
Login with LinkedIn
  • Register
  • Lost your password?

Or, sign up for our newsletter


Interesting links

Here are some interesting links for you! Enjoy your stay :)
© 2016-2022 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
Breast cancer update January 2021Breast-Cancer-Update-2021SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathySARS-CoV-2 infection in children and an increased risk of thrombotic microa...
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only
Copy link
CopyCopied
Powered by Social Snap
MediPaper Medical Communications Agency Hong Kong Blog